Biotech firm 180 Life Sciences has formally rebranded as ETHZilla following a strategic pivot to cryptocurrency treasury management.
The company announced a $425 million Private Investment in Public Equity (PIPE) offering priced at $2.65 per share, with participation from over 60 institutional and crypto-native investors. This capital forms the foundation of ETHZilla’s new Ethereum-focused treasury strategy.
ETHZilla aims to generate 3-10% annual yield through on-chain strategies developed in partnership with Electric Capital. The approach focuses on outperforming traditional Ethereum staking returns while reinvesting yield-generated proceeds to expand its ETH reserves.
Market response was positive, with ETHZilla’s stock (ATNF) rising 10% post-announcement. The company positions itself as a hybrid entity merging institutional capital with blockchain expertise to drive shareholder value within Ethereum’s financial infrastructure.